Sin categoría

At Wexford Laboratories, we are pleased to announce an important milestone for our organization and our valued business partners. Our manufacturing facilities in India have successfully obtained Good Manufacturing Practice (GMP) approval from Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID). This approval confirms that our manufacturing operations comply with the regulatory standards required … Read more

For many laboratories and distributors, incorporating cephalosporin antibiotics into their portfolio is often perceived as a complex, costly, and demanding process. Not because there is no market for the product, but because antibiotic manufacturing involves real challenges that not everyone is willing or able to take on. The good news is that today there are … Read more

Choosing a pharmaceutical manufacturer (CMO) is no longer just an operational decision. Today, it is a strategic decision that directly impacts time-to-market, regulatory compliance, supply continuity, and your brand’s reputation. Many pharmaceutical companies make the mistake of evaluating a manufacturer based only on price or capacity. However, a poor decision can result in delays, rework, … Read more

Pharmaceutical outsourcing has evolved from a cost-reduction strategy into a key decision for competing in a more demanding, dynamic, and globalized market. Today, companies are no longer just looking to manufacture. They are looking for speed, flexibility, and control. According to analyses from firms such as McKinsey and BCG, outsourcing continues to grow due to … Read more

Discover the Potential of Injectable Ferric Carboxymaltose with Wexford At Wexford Laboratories, we are proud to introduce a new addition to our portfolio: Injectable Ferric Carboxymaltose 50 mg/mL, an effective and efficient treatment for iron deficiency anemia, especially indicated for patients in dialysis programs. This innovative product offers multiple clinical and economic advantages, positioning it … Read more

New! Dexlansoprazole 60 mg Delayed-Release Capsules Wexford Laboratories is proud to present its latest pharmaceutical innovation: Dexlansoprazole 60 mg delayed-release capsules, a proton pump inhibitor (PPI) widely recommended for the treatment of erosive esophagitis, as well as gastric and duodenal ulcers. Patient Benefits Our Dexlansoprazole offers multiple advantages for patients requiring effective treatment for gastroesophageal … Read more

At Wexford Laboratories, we understand market trends and work to meet the needs of our clients. Today, we want to share a glimpse of the most in-demand medications in 2024 and demonstrate how we can be your trusted partner in manufacturing these essential products. The Bolivian Institute of Foreign Trade (IBCE) reports statistics related to … Read more

At Wexford, we don’t just focus on manufacturing formulations; we also strive to stay informed and up-to-date on everything happening in the global pharmaceutical field. Yes, at Wexford, we do the fieldwork for you! This year, we sent a team from Wexford Laboratories to one of the most prominent pharmaceutical expos in the world. The … Read more

Wexford Laboratories now has available one of the most commonly used antiemetics for the treatment of Nausea and Vomiting: Ondansetron 4 mg/2 mL Injectable Solution, a product highly utilized by Oncologists and Surgeons. If you want to discover how our New Formulation can revitalize your product portfolio and help you stay at the forefront of … Read more

Wexford Laboratories Adds Dexketoprofen 50mg/2ml Injectable Solution to Its Product List, Offering Rapid and Effective Relief for Acute Pain March 2024: In a continuous effort to improve the quality of life for patients suffering from acute pain, Wexford Laboratories is proud to announce the launch of its new product: Dexketoprofen 50mg/2ml Injectable Solution. This innovative … Read more